JP2017514522A - ヒト化可変性リンパ球受容体（ｖｌｒ）および組成物ならびにそれに関連する使用 - Google Patents

ヒト化可変性リンパ球受容体（ｖｌｒ）および組成物ならびにそれに関連する使用 Download PDF

Info

Publication number
JP2017514522A
JP2017514522A JP2017510445A JP2017510445A JP2017514522A JP 2017514522 A JP2017514522 A JP 2017514522A JP 2017510445 A JP2017510445 A JP 2017510445A JP 2017510445 A JP2017510445 A JP 2017510445A JP 2017514522 A JP2017514522 A JP 2017514522A
Authority
JP
Japan
Prior art keywords
amino acid
certain embodiments
acid sequence
seq
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017510445A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017514522A5 (https=
Inventor
アール． ヘリン，ブラントレイ
アール． ヘリン，ブラントレイ
デイル クーパー，マックス
デイル クーパー，マックス
エーアハルト，ルドルフ
Original Assignee
エモリー ユニバーシティー
エモリー ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エモリー ユニバーシティー, エモリー ユニバーシティー filed Critical エモリー ユニバーシティー
Publication of JP2017514522A publication Critical patent/JP2017514522A/ja
Publication of JP2017514522A5 publication Critical patent/JP2017514522A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2017510445A 2014-05-02 2015-04-30 ヒト化可変性リンパ球受容体（ｖｌｒ）および組成物ならびにそれに関連する使用 Pending JP2017514522A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461987566P 2014-05-02 2014-05-02
US61/987,566 2014-05-02
PCT/US2015/028645 WO2015168469A1 (en) 2014-05-02 2015-04-30 Humanized variable lymphocyte receptors (vlr) and compositions and uses related thereto

Publications (2)

Publication Number Publication Date
JP2017514522A true JP2017514522A (ja) 2017-06-08
JP2017514522A5 JP2017514522A5 (https=) 2018-06-14

Family

ID=54359347

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017510445A Pending JP2017514522A (ja) 2014-05-02 2015-04-30 ヒト化可変性リンパ球受容体（ｖｌｒ）および組成物ならびにそれに関連する使用

Country Status (8)

Country Link
US (3) US10167330B2 (https=)
EP (1) EP3137496A4 (https=)
JP (1) JP2017514522A (https=)
KR (1) KR20160147787A (https=)
CN (1) CN106459173A (https=)
CA (1) CA2947429A1 (https=)
IL (1) IL248327A0 (https=)
WO (1) WO2015168469A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017514522A (ja) 2014-05-02 2017-06-08 エモリー ユニバーシティー ヒト化可変性リンパ球受容体（ｖｌｒ）および組成物ならびにそれに関連する使用
SE1500434A1 (en) * 2015-10-29 2017-04-30 Theravac Pharmaceuticals Ab A novel fusion partner for highly efficient and safe vaccines
CN107365387B (zh) 2016-05-12 2022-03-15 阿思科力(苏州)生物科技有限公司 一种双特异性抗原结合构建体及其制备方法和应用
US11339225B2 (en) * 2016-05-12 2022-05-24 Asclepius (Suzhou) Technology Company Group, Co., Ltd. Bispecific antigen-binding construct and preparation method and use thereof
CN106543278B (zh) 2016-12-06 2019-04-12 阿思科力(苏州)生物科技有限公司 融合蛋白Slit2D2(C386S)-HSA及其在治疗纤维化疾病中的应用
JP2020505472A (ja) * 2017-01-27 2020-02-20 ボード オブ スーパーバイザーズ オブ ルイジアナ ステート ユニバーシティ アンド アグリカルチュアル アンド メカニカル カレッジ 自己免疫性糖尿病のための二官能性低分子ペプチド
US20200048321A1 (en) * 2017-03-24 2020-02-13 Orpheus Bioscience Inc. Pantids for treatment of autoimmune disorders
SG11201909160WA (en) * 2017-04-11 2019-10-30 Inhibrx Inc Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
KR101972894B1 (ko) * 2017-05-18 2019-04-29 경상대학교산학협력단 소수성 테일 도메인이 제거된 먹장어 유래 vlrb 단백질에 칠성장어 유래 vlrb 단백질의 c 말단 서열이 연결된 융합 단백질 및 이의 용도
KR20260046525A (ko) 2018-04-11 2026-04-07 인히브릭스 바이오사이언스, 인크. 제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 관련된 방법 및 용도
EP3827019A1 (en) 2018-07-24 2021-06-02 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
JP7611820B2 (ja) 2018-10-11 2025-01-10 インヒブルクス バイオサイエンシズ インコーポレイテッド Ｄｌｌ３シングルドメイン抗体およびその治療用組成物
JP2022504802A (ja) 2018-10-11 2022-01-13 インヒブルクス インコーポレイテッド ５ｔ４シングルドメイン抗体およびその治療組成物
US12077609B2 (en) 2018-12-21 2024-09-03 Wisconsin Alumni Research Foundation Variable lymphocyte receptors that target the brain extracellular matrix and methods of use
WO2020167735A1 (en) 2019-02-11 2020-08-20 Wisconsin Alumni Research Foundation Variable lymphocyte receptors that target the blood brain barrier and methods of use
JP7849292B2 (ja) * 2019-11-12 2026-04-21 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 潜伏形態のトキソプラズマ症についての新たな血清マーカー
JP2024527977A (ja) * 2021-07-27 2024-07-26 ノヴァブ， インコーポレイテッド 免疫エフェクター機能を有する操作されたｖｌｒｂ抗体
CN114891799B (zh) * 2022-05-20 2024-10-11 宁波大学 中华绒螯蟹可变淋巴受体vlr2基因及其编码的蛋白和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1118777A (ja) * 1997-07-09 1999-01-26 Asahi Chem Ind Co Ltd 新規スリット様ポリペプチド
JP2008500064A (ja) * 2004-05-21 2008-01-10 ザ ユーエービー リサーチ ファウンデーション 可変性リンパ球受容体、その関連ポリペプチドおよび核酸、ならびにその使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2659574C (en) 2006-08-02 2017-04-25 The Uab Research Foundation Methods and compositions related to soluble monoclonal variable lymphocyte receptors of defined antigen specificity
US9127087B2 (en) 2008-12-01 2015-09-08 University Of Maryland, Baltimore High affinity recombinant sea lamprey antibodies selected by a Yeast Surface Display platform
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2013078425A1 (en) 2011-11-22 2013-05-30 University Of Maryland, Baltimore Lambodies with high affinity and selectivity for glycans and uses therefor
CN103033617B (zh) * 2012-11-30 2014-12-03 辽宁师范大学 基于可变淋巴细胞受体的肿瘤标志物检测试剂盒及其制备方法
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
JP2017514522A (ja) 2014-05-02 2017-06-08 エモリー ユニバーシティー ヒト化可変性リンパ球受容体（ｖｌｒ）および組成物ならびにそれに関連する使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1118777A (ja) * 1997-07-09 1999-01-26 Asahi Chem Ind Co Ltd 新規スリット様ポリペプチド
JP2008500064A (ja) * 2004-05-21 2008-01-10 ザ ユーエービー リサーチ ファウンデーション 可変性リンパ球受容体、その関連ポリペプチドおよび核酸、ならびにその使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DRUG DESIGN REVIEWS ONLINE, 2005, VOL.2, P.305-322, JPN6019008815, ISSN: 0003996149 *
PNAS, 2012, VOL.109, P.3299-3304, JPN6019008817, ISSN: 0003996150 *
SCIENCE, 2008, VOL.321, P.1834-1837, JPN6019008810, ISSN: 0003996148 *

Also Published As

Publication number Publication date
WO2015168469A1 (en) 2015-11-05
US10167330B2 (en) 2019-01-01
US20190202887A1 (en) 2019-07-04
US20200308247A1 (en) 2020-10-01
KR20160147787A (ko) 2016-12-23
EP3137496A4 (en) 2017-10-11
CN106459173A (zh) 2017-02-22
EP3137496A1 (en) 2017-03-08
US20170081385A1 (en) 2017-03-23
CA2947429A1 (en) 2015-11-05
IL248327A0 (en) 2016-11-30
US11384134B2 (en) 2022-07-12

Similar Documents

Publication Publication Date Title
US11384134B2 (en) Recombinant vector and expression system comprising a nucleic acid encoding a variable lymphocyte receptor (VLR)
US11136369B2 (en) Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer
JP7533898B2 (ja) 血中半減期の向上のための抗体Ｆｃ変異体
CA2960466C (en) Cancer cell-specific antibody, anticancer drug and cancer testing method
EP3720959B1 (en) Selecting for developability of polypeptide drugs in eukaryotic cell display systems
CN109069639B (zh) Gitr抗体、方法及用途
JP2019193652A (ja) 前立腺特異幹細胞抗原に対する抗体およびその使用
CN111247429B (zh) 用于新颖抗原结合模块的特异性测试的通用报告细胞测定法
CN111742220A (zh) 检测癌症患者中的肿瘤抗原的诊断性测定法
CN110642947B (zh) 抗人cd147的单克隆抗体、表达载体、细胞株及其应用
AU2017348982B2 (en) Aglycosylated antibody Fc region for treating cancer
CN117279937A (zh) Epcam结合分子及其用途
CN116829161A (zh) 嵌合抗原受体t细胞及方法
US12491255B2 (en) EPCAM binding fibronectin type III domains
WO2025059589A1 (en) Immune cell engaging molecules
WO2024231348A1 (en) Slc4a4/nbce1 inhibitors
CN119751684A (zh) 一种抗psma的抗原结合片段、抗体及其应用
HK40031558A (en) Universal reporter cell assay for specificity test of novel antigen binding moieties
HK40031558B (zh) 用於新颖抗原结合模块的特异性测试的通用报告细胞测定法
HK1205149B (en) Target-tissue-specific antigen-binding molecule

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180427

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190319

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190808

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191001

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200401

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200526